Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of glucagon on physical capacity and metabolism in HFpEF with or without MASLD
2025-521835-35-00Phase 2Authorised
- Sponsor
- Katholisches Klinikum Bochum
- Start
- Nov 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glucagon in heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Katholisches Klinikum Bochum. Primary endpoint: Change in VO2max. Planned start Nov 2025; status: authorised.
02
Drugs
glucagon
03
Conditions
heart failure with preserved ejection fraction (HFpEF)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2025-521835-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521835-35-00.